DUBLIN, May 9, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Global Breast Cancer Predictive Genetic Testing Market Outlook 2022" report to their offering.

Global Breast Cancer Predictive Genetic Testing Market Outlook 2022 report analyzes the various aspects related to the emergence and development of breast cancer genetic test market across the globe.

The current and future aspects of cancer genomics have covered a long path of advances and the journey is still ongoing. The technological improvements in genomic sciences had allowed parallel sequencing of both tumors and germline mutations and had provided the weapon of next generation sequencing. Under the supervision of intellectual property laws and appropriate guidelines cancer susceptibility testing has become one of the major assets in medical practice. There appears to be pervasive belief in both scientific and public circles that genetic testing is going to be the cornerstone of much, if not all, of what medicine holds for the future. Besides, what is generally meant is the wide scale testing for susceptibility to common diseases especially for cancer and for responsiveness to drugs has come to be described as genetic profiling.

With the knowledge and acceptance of the fact that the breast cancer is on alarming scale, the major concern has been diverted towards this scenario. As there are 5% to 10% of breasts cancer cases which occur due to the germline mutations and the most common ones are the BRCA1 and BRCA2 mutations. Fortunately, these hereditary cancers can be prevented if diagnosed early or even before its occurrence which includes the susceptibility testing of breast cancer genes.

Leading to the current scenario which is completely changing and the market is now subjected to the direct to consumer BRCA testing kits provided by varied pharmaceuticals. However, the new entrants to the global market will face considerable challenges in persuading physicians to choose them as a test provider. New entrants will need to provide indication of subsequent in meeting the requirements of physicians such as reputation, trust, transparency, and counseling. Some of these aspects cannot be established quickly, and take time to establish.

Key Topics Covered:

1. Cancer Susceptibility Testing
1.1 Prologue to Cancer Susceptibility
1.2 Aspects of Cancer Susceptibility Testing

2. Breast Cancer Susceptibility
2.1 Conceptual of Breast Cancer Susceptibility
2.2 Trail of the Inherited Susceptible Genes

3. Hereditary Breast Cancer Genes
3.1 High Penetrant Genes
3.1.1 Breast Cancer Gene1 (BRCA1)
3.1.2 Breast Cancer Gene 2 (BRCA2)
3.1.3 TP53
3.1.4 PTEN
3.1.5 STK11 & CDH1
3.2 Intermediate Penetrant Genes
3.2.1 CHEK2
3.2.2 PALB2
3.2.3 ATM
3.2.4 Other Genes
3.3 Low Penetrant Genes

4. Breast Cancer Susceptible Syndromes
4.1 Hereditary Breast & Ovarian Cancer
4.2 Cowden Syndrome
4.3 Li-Fraumeni Syndrome
4.4 Peutz-Jeghers Syndrome

5. Cancer Susceptibility Testing Essentials
5.1 Prerequisites towards Cancer Susceptibility
5.2 Sequential Stages in Testing

6. Genetic Cancer Susceptibility Testing
6.1 Risk Assessment
6.2 Genetic Counseling
6.3 Genetic Testing
6.4 Post-Test Counseling

7. Management of Hereditary Risk
7.1 Surveillance
7.2 Chemoprevention
7.3 Bilateral Prophylactic Mastectomy

8. Economical, Ethical & Social Aspects
8.1 Economic Aspects of Cancer Susceptibility Testing
8.2 Ethical Aspects of Cancer Susceptibility Testing
8.3 Social Aspects of Cancer Susceptibility Testing

9. Global Prevalence of Breast Cancer
9.1 Breast Cancer Incidences
9.2 Germline Breast Cancer Ethnicity

10. Prevalence over Geographic Regions

11. Preface of Monetary Prospects
11.1 Cost of Breast Cancer Susceptibility Testing
11.2 Insurance Affairs for Breast Cancer Susceptibility Testing

12. Aspects of Cancer Susceptibility Market
12.1 Breast Cancer Susceptibility Market Overview
12.2 Direct To Consumer Market

13. Global Breast Cancer Predictive Genetic Testing Market Dynamics
13.1 Accelerative Parameters
13.2 Challenges

14. Global Breast Cancer Predictive Genetic Testing Market Future Aspects

15. Competitive Landscape

• Cancer Genetics
• Invitae
• Iverson Genetics
• Myriad Genetics
• NeoGenomics
• Oncocyte
• PerkinElmer
• Quest Diagnostics
• Roche
• Thermo Fisher Scientific

For more information about this report visit http://www.researchandmarkets.com/research/jkrv3m/global_breast

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Related Links

http://www.researchandmarkets.com

SOURCE Research and Markets